1. Dual drug delivery via integrin-targeted nanoparticles enhances therapeutic efficiency in BRAFV600E colon cancer
Sen R, Alnatour M, Janardhanam Lsl, Anjum Mm, Naguib Yw, Geary Sm, Et Al.
Colorectal cancer (CRC) patients possessing the BRAF V600E mutation often fail to respond to current first line therapies and are associated with poor prognosis, despite the advent of orally delivered small molecule inhibitors (SMIs) targeting the RAS-RAF-MEK-ERK signaling pathway. Thus, further improvements are…
Read the article